Entegrion Announces Organizational Changes to Support Advanced Product Development
Entegrion, the life sciences product development company focused on improving the safety and availability of the world´s blood supply, announces management team changes and a clinical advisory board. The leadership will provide guidance as the company’s biologic and medical device technologies move into advanced development; Entegrion has announced DOD contract awards over the past three years totaling more than $50 million for the development of resuscitation and coagulation technologies.
Research Triangle Park, NC (PRWEB) June 19, 2013
North Carolina-based life sciences company Entegrion, Inc., announced organizational changes to advance development of its technologies.
Entegrion´s Executive Chairman John B. Mowell said, “To support the advanced development of our product candidates Entegrion´s Board of Directors has made changes to the Company´s management structure and engaged industry leaders as key advisors.”
The Company announced that Michael Galiger will serve as Vice President of Operations with primary responsibility for development of Entegrion´s plasma product Resusix, as well as supporting the continued advancement of the Company´s other technologies. “Mike´s technical background, intensive work with the development of Entegrion´s products, and his success in attracting a solid product development team, including Stacy Hammonds as Director of Clinical Operations, and Taegen Sullivan, Product Development Engineer, have made a substantial contribution to Entegrion´s success,” Mowell continued.
Entegrion also announced the formation of a clinical advisory Board initially comprised of Paul Ness, MD, Director of Transfusion Medicine at Johns Hopkins; Professor Peter Rhee, MD, Chief of Trauma, Critical Care, Burns and Emergency Surgery, University of Arizona; Edward Scott, MD, President of Key Biologics; and Philip C. Spinella, MD, Director, Pediatric Critical Care Translational Research Program, Washington University, St. Louis.
“We are immensely proud to be associated with these world-class leaders in transfusion and trauma medicine. Drs. Rhee and Spinella both came out of the Armed Forces and served in Iraq. They will bring a unique ℠user perspective´ to our technologies. Dr. Scott has decades of experience with the supply of blood and blood derivatives, and Dr. Ness is an expert in transfusion medicine. Their guidance will be invaluable as our biologic and medical device technologies move into advanced development,” Mowell said.
Entegrion also announced that Richard Martin will serve as Executive Vice President with responsibility for Entegrion´s overall day-to-day business operations reporting to the Executive Chairman, and will assist in the areas of strategic corporate planning and development. Susan Reyer, the Company´s Controller for the past five years, now serves as Vice President, Chief Financial Officer, with responsibility for the Company´s financial and administrative matters.
Joseph DaCorta will continue in his role as Chief Technology Officer, with responsibility for managing Entegrion´s government relations and exploring new opportunities to utilize the Company´s technologies. Arthur Bode continues to serve as Vice President, Chief Science Officer in charge of scientific research and project support.
Mowell stated, “We are fortunate that each of the senior members of our management team have been integral to the company´s operations for a number of years, positioning Entegrion well for continued success.”
Over the past three years, Entegrion has announced Department of Defense contract awards totaling more than $50 million for the development of resuscitation and coagulation technologies that have important healthcare applications for US Armed Forces.
Entegrion, Inc. is a life sciences product development company that is focused on improving the safety and availability of the world´s blood supply. Based in North Carolina´s Research Triangle Park, Entegrion offers patented technologies designed to overcome limitations in storage, safety, and availability of blood-derived products while preserving their functionality. Many of Entegrion´s advances in biologics are based on close collaborations with leading medical research institutions. Visit http://www.entegrion.com for more information.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013EntegrionLeadership/06Updates/prweb10848250.htm